Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 6/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL352185 | 0.98 | ALDH1A1 (0.49) | ALDH1A1HSD17B10CYP1A2LMNACYP3A4 | |
| SCHEMBL28145775 | 0.83 | ALDH1A1 (0.55) | ALDH1A1HSD17B10CYP1A2LMNACYP3A4 | |
| SCHEMBL29659326 | 0.82 | PTGER4 (0.44) | ALDH1A1HSD17B10CYP1A2LMNACYP3A4 | |
| SCHEMBL1149707 | 0.81 | KDM4E (0.47) | ALDH1A1CYP1A2LMNACYP3A4MAOA | |
| SCHEMBL15090763 | 0.80 | KDM4E (0.46) | ALDH1A1CYP1A2LMNACYP3A4MAOA | |
| SCHEMBL2069470 | 0.80 | KMT2A (0.56) | ALDH1A1HSD17B10CYP1A2LMNAKDM4E | |
| SCHEMBL6778868 | 0.80 | CA12 (0.52) | ALDH1A1CYP1A2KDM4EGAAHPGD | |
| SCHEMBL16236949 | 0.80 | KDM4E (0.46) | ALDH1A1CYP1A2LMNAKDM4EGAA | |
| Hydrochloric Acid SCHEMBL2117780 | 0.80 | KDM4E (0.46) | ALDH1A1CYP1A2LMNACYP3A4MAOA | |
| SCHEMBL27969448 | 0.79 | ALDH1A1 (0.46) | ALDH1A1HSD17B10KDM4EGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120006267-A | Lead-free medium phosphorus chemical nickel plating solution | 珠海联鼎化工设备有限公司 | 2025-05-16 | — | — | CN | claimed |
| CN-117088905-A | Asymmetric boron-fluorine pyrrole fluorescent dye, preparation method thereof and method for preparing fluorescent microspheres | 南京珀立科技有限公司 | 2023-11-21 | — | — | CN | claimed |
| EP-2077268-B1 | Process for preparing inhibitors of nucleoside metabolism | VICTORIA LINK LTD (NZ) | 2017-03-01 | — | — | EP | claimed |
| EP-2077268-A1 | Process for preparing inhibitors of nucleoside metabolism | Industrial Research Limited (NZ) | 2009-07-08 | — | — | EP | claimed |
| US-7405297-B2 | Process for preparing inhibitors of nucleoside metabolism | INDUSTRIAL RESEARCH LIMITED (NZ) | 2008-07-29 | — | — | US | claimed |
| US-20070161667-A1 | Process for preparing inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2007-07-12 | — | — | US | claimed |
| US-7211677-B2 | Process for preparing inhibitors of nucleoside metabolism | INDUSTRIAL RESEARCH LIMITED (NZ) | 2007-05-01 | — | — | US | claimed |
| US-20060089498-A1 | Process for preparing inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2006-04-27 | — | — | US | claimed |
| US-20040181063-A1 | Process for preparing inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2004-09-16 | — | — | US | claimed |
| EP-1165564-A4 | PROCESS FOR PREPARING INHIBITORS OF NUCLEOSIDE METABOLISM | IND RES LTD (NZ) | 2003-01-22 | — | — | EP | claimed |
| EP-1165564-A2 | PROCESS FOR PREPARING INHIBITORS OF NUCLEOSIDE METABOLISM | INDUSTRIAL RESEARCH LIMITED (NZ) | 2002-01-02 | — | — | EP | claimed |
| WO-2000061783-A2 | PROCESS FOR PREPARING INHIBITORS OF NUCLEOSIDE METABOLISM | INDUSTRIAL RESEARCH LIMITED (NZ) | 2000-10-19 | — | — | WO | claimed |
| US-20260098041-A1 | FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS | INCYTE CORPORATION (US) | 2026-04-09 | — | — | US | disclosed |
| US-12569489-B2 | 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase | ASTRAZENECA AB (SE) | 2026-03-10 | — | — | US | disclosed |
| WO-2025245472-A1 | COMPOUNDS AND RELATED METHODS USEFUL FOR DEGRADATION OF CYCLIN K AND INHIBITION OF CYCLIN DEPENDENT KINASES | REMIX THERAPEUTICS INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-4573096-A1 | INHIBITORS OF MYELOPEROXIDASE | Astrazeneca AB (SE) | 2025-06-25 | — | — | EP | disclosed |
| WO-2000061783-A2 | PROCESS FOR PREPARING INHIBITORS OF NUCLEOSIDE METABOLISM | INDUSTRIAL RESEARCH LIMITED (NZ) | 2000-10-19 | — | — | WO | disclosed |
| US-5688800-A | ANTITUMOR AGENTS | EISAI CO., LTD. (JP) | 1997-11-18 | — | — | US | disclosed |
| US-5554615-A | ANTITUMOR | EISAI CO., LTD. (JP) | 1996-09-10 | — | — | US | disclosed |
| EP-0530579-A1 | Condensed pyrimidine derivatives antitumor agents | Eisai Co., Ltd. (JP) | 1993-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098041-A1 | FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS | WRN, POLR1A, REV1 | ALDH1A1 1354/4885HSD17B10 1837/4885CYP1A2 3621/4885 |
| US-20060089498-A1 | Process for preparing inhibitors of nucleoside metabolism | UGT1A3, AGL, PNP | ALDH1A1 2979/4885HSD17B10 1117/4885CYP1A2 85/4885 |
| US-20040181063-A1 | Process for preparing inhibitors of nucleoside metabolism | XDH, PNP, AGL | ALDH1A1 1853/4885HSD17B10 1080/4885CYP1A2 42/4885 |
| US-20070161667-A1 | Process for preparing inhibitors of nucleoside metabolism | PNP, UGT1A3, AGL | ALDH1A1 2849/4885HSD17B10 1101/4885CYP1A2 93/4885 |
| US-12569489-B2 | 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase | MPO, EPX, LPO | ALDH1A1 307/4885HSD17B10 1105/4885CYP1A2 1499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.